The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 6th 2024
The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Karin Schenck-Gustafsson, MD, PhD, FESC: Why Sex and Gender Must be Considered in Disease Treatment
Karin Schenck-Gustafsson, MD, PhD, FESC, explains why sex and gender must be taken into account when treating and managing patients with rheumatic disease from a cardiologist's perspective.
Line Uhrenholt, MD: Disease Activity-Guided Tapering in Patients with Inflammatory Arthritis
Line Uhrenholt, MD, discusses the results of her randomized, open-label, equivalence trial study evaluating disease activity-guided tapering of biologics in patients with inflammatory arthritis.
Rheumatoid Arthritis Quiz: Bridging Therapy
June 6th 2022Glucocorticoids are sometimes used as “bridging” therapy to alleviate symptoms in newly diagnosed patients with rheumatoid arthritis (RA) prescribed a disease-modifying antirheumatic drug (DMARD), until the DMARD kicks in. Test your knowledge of bridging therapy with this quiz.
Patient-Provider Satisfaction Survey Affected by Cultural Norms in Hispanic/Latinx Patients with RA
A recent study, conducted by CreakyJoints, demonstrated that patient-reported satisfaction is affected by both social and cultural norms in Spanish-speaking patients with rheumatoid arthritis.
Filip Van den Bosch, MD: Safety and Efficacy of Upadacitinib for nr-axSpA
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
Albert Roy: Clinically Significant Phase 2 Data Evaluates Deucravacitinib for SLE Treatment
Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.
Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment
June 3rd 2022Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.